한글목차

• GlobalData의 RP 관련 역학 예측에 따르면, 2024년 16개국에서 100만 명 이상의 RP 환자가 진단될 것으로 예상됩니다.
• RP 치료 가이드라인은 전 세계적으로 확립되어 있으며, Roche의 Luxturna(voretigene neparvovec)가 RP 시장을 독점하고 있습니다.
• RP의 파이프라인 자산의 대부분은 단백질과 펩타이드 활성화제이며, 그 다음이 수용체 활성화제입니다.
• 지난 10년간 총 107건의 RP 임상시험이 시작되었으며, 3상 임상시험이 전체의 12.15%를 차지합니다.
• 남미, 아프리카, 아시아태평양, 북미에서는 라이선스 계약이 주류를 이루었습니다. 유럽에서는 파트너십 계약이 크게 확대되었습니다.

이 보고서는 세계 망막색소변성증(RP) 시장을 조사 분석하여 질병 현황, 시판 중인 약물 및 파이프라인 약물 평가, 현재와 미래의 경쟁 상황 등을 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질환 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시약 평가

• 주요 출시약
• 개요 : 작용기서별
• 개요 : 투여 경로별
• 출시약 프로파일과 판매량 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인약 평가

• 단계 III 파이프라인약
• 개요 : 개발 단계별
• 개요 : 분자 유형별
• 개요 : 작용기서별
• 개요 : 투여 경로별
• 약품 고유의 단계 이동 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야와 적응증 고유의 PTSR과 LoA

제7장 임상시험 평가

• 과거 개요
• 개요 : 단계별
• 개요 : 상황별
• 개요 : 단계별(진행중/계획된 시험)
• 가상 컴포넌트에 의한 시험
• 지역적 개요
• 단일국/다국간 시험 : 지역별
• 스폰서 상위 20개사와 내역 : 단계별
• 스폰서 상위 20개사와 내역 : 상황별
• 개요 : 엔드포인트 상황별
• 개요 : 인종/민족별
• 등록 데이터
• 시험 시설 상위 20개국
• 세계의 상위 20개 시설
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

• 합병, 인수, 전략적 제휴 : 지역별
• 최근 합병, 인수, 전략적 제휴

제9장 상업적 평가

• 주요 시장 기업

제10장 향후 시장 촉매

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in RP therapeutics.

• More than 1,000,000 diagnosed prevalent cases of RP are expected in 2024 in the 16 countries covered in GlobalData's epidemiology forecast for RP.
• The treatment guidelines for RP have been well established globally. Roche's Luxturna (voretigene neparvovec) dominate the RP market.
• Majority of RP pipeline assets are protein and peptide activator, followed by receptor activator.
• A total of 107 clinical trials were initiated for RP in the past 10 years, Phase III trials made up 12.15% of the total trials.
• Licensing agreement was the predominant deal type in South America, Africa, Asia-Pacific and North America. In Europe, partnership deals were notably widespread.

Scope

GlobalData's RP: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the RP market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RP market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Route of Administration
• 4.4 Marketed Drugs Profiles and Sales Forecasts

5 Pricing and Reimbursement Assessment

• 5.1 Annual Therapy Cost
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Phase III Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Molecule Type
• 6.4 Overview by Mechanism of Action
• 6.5 Overview by Route of Administration
• 6.6 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.7 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Geographic Overview
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer